Raymond R. Mattingly is Professor and Chair of Pharmacology and Toxicology at the Brody School of Medicine at East Carolina University. He was previously Chair of Pharmacology at Wayne State University, where he retains an emeritus appointment. He received his BA in Natural Sciences and Pharmacology in 1987 from the University of Cambridge with double first-class honors and his PhD in pharmacology from the University of Virginia in 1993. His research seeks to identify effective, new therapeutic approaches to cancers that are driven through Ras signal transduction pathways in the absence of a direct oncogenic mutation of Ras. This mechanistic strand underlies both type 1 neurofibromatosis (NF1) and many cases of breast cancer. He established three-dimensional (3D) cell culture models of multiple sub-types of human breast cancer in order to provide tractable and relevant systems in which to identify targeted therapeutics. In the context of NF1, he developed co-cultured 3D models of plexiform neurofibromas for screening of compound libraries. He has optimized and validated findings in animal models and patient samples with the goal of translating the work into the clinic. He is a member of the American Society for Pharmacology and Experimental Therapeutics (ASPET), the American Association for Cancer Research (AACR), and the Association of Medical School Pharmacology Chairs (AMSPC). He has won numerous teaching awards and is a Fellow of Pharmacology Educators of ASPET.